PDF factsheet
      Z

angiogenesis inhibitors in advanced breast cancer (metastatic) for all type of patients, clinical trials results

bevacizumab + capecitabine versus capecitabine
AVF2119g (Miller) cape, 2005
capecitabine + bevacizumab 15 mg/kg iv every 3 weeks
versus
capecitabine (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks
patients with metastatic breast cancer previously treated with an anthracycline and a taxaneopen
US
RIBBON-I (Robert) on top capecitabine, 2009
Capecitabine + bevacizumab 15 mg/kg iv every 3 weeks
versus
capecitabine (Cape; 2,000 mg/m(2) for 14 days),
irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancerdouble-blind
bevacizumab + docetaxel versus docetaxel
AVADO (Miles) 7.5mg, 2010
bevacizumab 7.5mg/kg every 3 weeks plus docetaxel
versus
placebo plus docetaxel
first-line treatment of HER2-negative metastatic breast cancer double-blind
AVADO (Miles) 15mg , 2009
Docetaxel + bevacizumab 7.5 mg/kg iv every 3 weeks
versus
first-line treatment of HER2-negative metastatic breast cancer
bevacizumab + endocrine therapy versus endocrine therapy
LEA,
bevacizumab + letrozole/fulvestrant
versus
letrozole or fulvestrant
first-line therapy in postmenopausal patients with human epidermal growth factor receptor 2 (HER2) -negative and hormone receptor-positive advanced breast cancer
bevacizumab + methotrexate versus methotrexate
Burstein, 2005
Methotrexate + cyclophosphamide + bevacizumab 10 mg/kg iv every 2 weeks
versus
bevacizumab + paclitaxel versus paclitaxel
Martin bevacizumab, 2011
bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle
versus
control
patients with HER2-negative locally recurrent or metastatic breast canceropen design
bevacizumab + taxanes versus taxanes
E2100 (Miller), 2007
NCT00028990
paclitaxel + bevacizumab 10 mg/kg iv every 2 weeks
versus
paclitaxel 90 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks
patients with metastatic breast cancer not previously treatedopen
RIBBON-I (Robert) on top Tax or anthra, 2009
Taxanes or anthracyclines + bevacizumab 15 mg/kg iv every 3 weeks
versus
taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2)), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, o
irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
bevacizumav + CT versus CT alone
RIBBON-2 (Brufsky), 2009
addition of BV to chemotherapies used as second-line treatment for MBC
versus
chemo+placebo
second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast canceropen
19 countries
cediranib + fulvestrant versus fulvestrant
Hyams,
NCT00454805

versus
enzastaurin + fulvestrant versus Fulvestrant
De Jong,

versus
Letrozole plus bevacizumab versus letrozole
Dickler (CALGB 40503°, 2015

versus
motesanib + paclitaxel versus paclitaxel
Martin (motesanib), 2011
NCT00356681
motesanib 125 mg orally once per da
versus
placebo
patients with untreated HER2-negative metastatic breast cancerdouble-blind
sorafenib + gemcitabine or capecitabine versus gemcitabine or capecitabine alone
Schwartzberg, 2013
NCT00493636
sorafenib (400 mg, twice daily)
versus
placebo
patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumabdouble-blind
sorafenib + paclitaxel versus paclitaxel alone
Gradishar, 2013
paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) plus sorafenib (400mg, orally, twice daily)
versus
paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off)
first-line therapy in patients with HER2-negative advanced breast cancerdouble-blind

  Options


in first

in second

  Filter